Amer Beitinjaneh, MD, MSc, MPH, FACP, on Treating EBV+ PTLD With Tab-cel
The associate professor of medicine at Sylvester Comprehensive Cancer Center discussed updated data from the phase 3 ALLELE study.
“For patients with EBV-positive Post-Transplant Lymphoproliferative Disorder who failed rituximab-based therapy, the outcome is usually very dismal... Median overall survival is often less than 4 months and there are currently no approved treatments indicated for those patients. So initially, we will use immune suppression and rituximab-based therapy, but once you fail, you will pretty much have no options.”
Tabelecleucel (tab-cel; Atara Biotherapeutics), an allogeneic Epstein–Barr virus (EBV)-specific T-cell immunotherapy, produced clinically meaningful outcomes and demonstrated a promising safety profile in patients with EBV-positive post-transplant lymphoproliferative disease (EBV+ PTLD) treated in the phase 3 ALLELE clinical trial (NCT03394365). Updated data from the trial were presented at the
CGTLive spoke with Beitinjaneh about the updated results from the ALLELE study. He discussed the unmet need that tab-cel can help address in patients with EBV+ PTLD. Tab-cel is approved in the European Union in the same indication.
REFERENCE
Beitinjaneh A, Baiocchi R, Choquet S, et al. New and updated results from a multicenter, open-label, global phase 3 (P3) study of tabelecleucel (Tab-cel) for Epstein–Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD) following allogeneic hematopoietic cell (HCT) or solid organ transplant (SOT) after failure of rituximab (R) or rituximab and chemotherapy (R+CT) (ALLELE). Presented at: 2023 Tandem Meetings, February 15-19, 2023; Orlando, Florida. Abstract #25.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- Around the Helix: Cell and Gene Therapy Company Updates – September 17, 2025
September 17th 2025
- ImmunoLogic, Episode 6: "The Future of Personalized Cancer Vaccines”
September 15th 2025
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025